Diphenhydramine dual antitussive/antihistamine indication approved in final rule.
This article was originally published in The Tan Sheet
Executive Summary
DIPHENHYDRAMINE DUAL INDICATION PERMITTED BY FDA pending the completion of the OTC cough/cold combination drug products final monograph. Under a final rule published by FDA in the April 9 Federal Register, effective immediately, OTC products containing either diphenhydramine citrate or diphenhydramine HCl can be labeled as both an antitussive and an antihistamine in single-ingredient and cough/cold combination products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning